JAK Inhibitors Reshape Alopecia Areata Care, Spanish Experts Say in New Consensus

For the millions of people living with alopecia areata (AA), the arrival of Janus kinase (JAK) inhibitors has fundamentally changed what treatment can look like, and a new national consensus from Spain, published in Actas Dermo-Sifiliográficas, offers dermatologists a detailed framework for putting these drugs and the full range of AA therapies into practice.¹

The Case for Updated Clinical Guidance

AA, an autoimmune inflammatory alopecia, affects roughly 2% of the general population over a lifetime and can present across a broad clinical spectrum, ranging from small circular scalp patches to total body hair loss. Despite this prevalence, clinicians have lacked clear, unified guidance on when and how to escalate therapy across the disease's many stages. The expansion of the treatment toolkit, particularly the regulatory approval of JAK inhibitors in Spain for patients with extensive AA who had failed systemic corticosteroids, made updated guidance urgent.

The human cost of that clinical uncertainty is well documented. A 2023 scoping review published in the Journal of the European Academy of Dermatology and Venereology found that quality-of-life impairment was present in more than 75% of people with AA, with up to one-third reporting extremely severe impairment.² The same review, which drew on 85 studies examining psychiatric comorbidities and 9 focused on work and school absenteeism, underscored that AA's burden extends well beyond the scalp—affecting mental health, productivity, and daily functioning in ways that standard clinical severity tools do not fully capture. That gap between measured disease extent and lived patient experience helped make the case for a consensus framework that weighs psychosocial factors alongside SALT scores.

To fill that gap, 23 dermatologists from the Spanish Hair Research Group of the Spanish Academy of Dermatology and Venereology (GET-AEDV) convened to develop a consensus document using a modified Delphi method.¹

Matching Treatment to Disease Severity

A scientific committee of 8 trichology specialists (each with more than 5 years of clinical experience) led a qualitative literature review covering publications in Spanish and English from 2013 onward. They then drafted 125 statements organized into 5 thematic blocks: general aspects, localized AA, moderate AA, extensive AA, and special situations.

All 23 panelists rated each statement on a 9-point Likert scale, with scores of 7 to 9 indicating agreement and 1 to 3 indicating disagreement. Consensus required a median response within one of those bands, fewer than one-third of votes outside the band, and an IQR of 3 or less.

After the first round, 99 items reached consensus. A second round was conducted on revised statements, yielding 2 additional agreements. In total, 101 of 125 items (81%) reached consensus.

The panel organized recommendations around the Severity of Alopecia Tool (SALT) scale, which classifies AA as localized (SALT 1; less than 20% scalp involvement), moderate (SALT 2; 20%-50%), or extensive (SALT 3-5; 50% or more).

For localized AA, panelists agreed that both watchful waiting and intralesional corticosteroid infiltrations were reasonable first options. Triamcinolone acetonide was positioned as the preferred infiltration agent over betamethasone, with maximum recommended concentrations of 12 mg/mL for the scalp and 4 mg/mL for the eyebrows and beard. High-potency topical corticosteroids were reserved for children and adults who could not tolerate intralesional therapy. Oral minoxidil was endorsed as an adjunct to improve hair density during regrowth.

For moderate AA, weekly systemic corticosteroid pulse therapy (for example, dexamethasone 0.1 mg/kg on 2 consecutive days per week) was agreed upon as the best step-up option after local therapy failed, with full-dose treatment limited to 3 to 6 months. When systemic corticosteroids proved insufficient, the panel endorsed adding immunosuppressants such as methotrexate, cyclosporine, or azathioprine.

For extensive AA, systemic corticosteroids remained the agreed-upon first-line treatment, but the panelists acknowledged their limitations candidly. As the authors stated, “Despite this treatment, most patients with extensive AA experience progression or relapses." JAK inhibitors, specifically ritlecitinib 50 mg/day and baricitinib 4 mg/day, were positioned as the treatment of choice in eligible patients who wished to receive therapy, with a minimum 9-month trial recommended before assessing effectiveness.

Special Population Guidance

The panel addressed several clinical scenarios that require modified approaches. For pediatric patients aged 12 and older with severe AA, the consensus supported initiating JAK inhibitor therapy, with parental consent, after weighing the risk of serious adverse effects against the psychosocial burden of the disease (Level of Evidence 1, Grade of Recommendation A). For children under 12, off-label JAK inhibitor use could be considered in cases of severe psychosocial impairment, with informed parental consent.

For pregnant patients, systemic treatment was to be deferred until after delivery. During breastfeeding, topical corticosteroids and local immunotherapy were recommended if treatment was deemed necessary.

Notably, no consensus was reached on proposals favoring less aggressive treatment in patients aged 65 and older, suggesting that clinicians should not limit therapeutic ambition based on age alone.

Screening Requirements and Vaccination Considerations

The panel specified pre-treatment screening requirements, including complete blood count, liver and renal function tests, lipid levels, serologies for hepatitis B, hepatitis C, and HIV, latent tuberculosis screening, and pregnancy testing in women of childbearing potential. Live attenuated vaccines were to be avoided during treatment or within four weeks before initiation. The panel also noted that reimbursement policies in Spain directly influenced JAK inhibitor prescribing in routine practice.

Prior Authorization and Coverage Decisions in a Shifting AA Treatment Landscape

The consensus was based on expert opinion and qualitative literature review rather than a systematic review or meta-analysis, and all panelists were Spanish dermatologists, which may limit the generalizability of recommendations to other health systems and reimbursement environments. Several items, including the specific administration schedule for intralesional corticosteroids and the role of topical minoxidil, did not reach consensus, pointing to areas where clinical evidence remains insufficient. The SALT scale itself was acknowledged as an imperfect tool, as it does not capture nail involvement, loss of facial or body hair, or patients' psychological status.

The consensus framework positions JAK inhibitors as a meaningful but resource-intensive option in the AA treatment continuum, underscoring the need for prior authorization pathways that account for disease severity and prior treatment failure. With new staging tools such as the Alopecia Areata Scale and the Alopecia Areata Severity and Morbidity Index also entering clinical discussion, payers and clinicians alike may soon have more holistic criteria for guiding coverage decisions in this evolving therapeutic landscape.

References

1. Saceda-Corralo D, Arias-Santiago S, Barrutia A, et al. Consensus document on the clinical management of alopecia areata: recommendations from the Spanish Hair Research Group of the Spanish Academy of Dermatology and Venerology. Actas Dermo-Sifiliográficas. 2026;117(6):104609. doi:10.1016/j.ad.2026.104609
2. Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023;37(8):1490-1520. doi:10.1111/jdv.18926